CL2017001756A1 - Régimen de dosificación para antagonistas de madcam. - Google Patents

Régimen de dosificación para antagonistas de madcam.

Info

Publication number
CL2017001756A1
CL2017001756A1 CL2017001756A CL2017001756A CL2017001756A1 CL 2017001756 A1 CL2017001756 A1 CL 2017001756A1 CL 2017001756 A CL2017001756 A CL 2017001756A CL 2017001756 A CL2017001756 A CL 2017001756A CL 2017001756 A1 CL2017001756 A1 CL 2017001756A1
Authority
CL
Chile
Prior art keywords
dosing regimen
madcam
patient
antagonists
madcam antagonists
Prior art date
Application number
CL2017001756A
Other languages
English (en)
Inventor
Fabio Cataldi
Robert A Clare
Gail M Comer
Vivekananda Pradhan
Alaa Ahmad
Mina Hassan-Zahraee
Mera Krishnan Tilley
Weidong Zhang
Anindita Banerjee
Karen Michelle Page
Michael Steven Vincent
Schack David J Von
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55275128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001756(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of CL2017001756A1 publication Critical patent/CL2017001756A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Abstract

<p>La presente invención proporciona un método para tratar a un paciente que comprende administrar al paciente una dosis inicial de entre alrededor de 1 mg y alrededor de 150 mg de anticuerpo antagonista de MAdCAM. También se proporcionan biomarcadores para evaluar la respuesta del paciente al tratamiento anti-MAdCAM. </p>
CL2017001756A 2015-01-09 2017-07-03 Régimen de dosificación para antagonistas de madcam. CL2017001756A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562101877P 2015-01-09 2015-01-09
US201562263197P 2015-12-04 2015-12-04
US201562263910P 2015-12-07 2015-12-07

Publications (1)

Publication Number Publication Date
CL2017001756A1 true CL2017001756A1 (es) 2018-02-09

Family

ID=55275128

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001756A CL2017001756A1 (es) 2015-01-09 2017-07-03 Régimen de dosificación para antagonistas de madcam.

Country Status (16)

Country Link
US (2) US10851163B2 (es)
EP (2) EP4112079A1 (es)
JP (2) JP6779621B2 (es)
KR (1) KR20170129104A (es)
CN (3) CN114377125A (es)
AU (2) AU2016205852B2 (es)
BR (1) BR112017014793A2 (es)
CA (1) CA2916283A1 (es)
CL (1) CL2017001756A1 (es)
EA (1) EA037288B1 (es)
ES (1) ES2927958T3 (es)
IL (1) IL253247B (es)
MA (1) MA41314A (es)
MX (1) MX2017009047A (es)
SG (1) SG11201705604WA (es)
WO (1) WO2016110806A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6904905B2 (ja) * 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
CA2916283A1 (en) * 2015-01-09 2016-07-09 Pfizer Inc. Dosage regimen for madcam antagonists
EP3630163A4 (en) * 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
CR20200076A (es) 2017-07-14 2020-06-10 Pfizer ANTICUERPOS CONTRA MAdCAM
CN108118093A (zh) * 2018-03-06 2018-06-05 谢琳 Linc00426在制备骨肉瘤转移诊断产品中的用途
CN112805566A (zh) * 2019-07-29 2021-05-14 上海谷森医药有限公司 用于吸入治疗肺癌的抗体类药物制剂
CN113789328A (zh) * 2021-09-16 2021-12-14 中国人民解放军海军军医大学 lncRNA及其在免疫调控及免疫相关疾病诊治中的应用
CN114164211B (zh) * 2021-09-16 2024-02-27 中国人民解放军海军军医大学 lncRNA及其在肿瘤诊断、治疗和预后判断中的应用
CN116631510B (zh) * 2022-10-28 2024-01-12 中国人民解放军军事科学院军事医学研究院 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
JP4315982B2 (ja) * 2004-01-09 2009-08-19 ファイザー インコーポレイティッド ＭＡｄＣＡＭに対する抗体
WO2006096488A2 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
EP1904531B1 (en) 2005-07-08 2010-10-06 Pfizer Limited Madcam antibodies
EP1904103A2 (en) 2005-07-08 2008-04-02 Pfizer Limited Use of anti-madcam antibodies for the treatment of coeliac disease and tropical sprue
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
WO2007007151A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007007160A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
DE102010013830A1 (de) * 2010-03-26 2011-09-29 Carl Zeiss Microlmaging Gmbh Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe
EP3495814A3 (en) * 2013-03-27 2019-07-17 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CA2916283A1 (en) 2015-01-09 2016-07-09 Pfizer Inc. Dosage regimen for madcam antagonists

Also Published As

Publication number Publication date
CA2916283A1 (en) 2016-07-09
MX2017009047A (es) 2019-01-30
US20180273619A1 (en) 2018-09-27
AU2021250850B2 (en) 2023-06-01
SG11201705604WA (en) 2017-08-30
AU2016205852B2 (en) 2021-09-16
US11884726B2 (en) 2024-01-30
AU2016205852A1 (en) 2017-07-20
KR20170129104A (ko) 2017-11-24
EP3242684B1 (en) 2022-07-27
ES2927958T3 (es) 2022-11-14
BR112017014793A2 (pt) 2018-01-09
JP2021011493A (ja) 2021-02-04
US10851163B2 (en) 2020-12-01
JP2016128441A (ja) 2016-07-14
CN107427576A (zh) 2017-12-01
JP6779621B2 (ja) 2020-11-04
EP4112079A1 (en) 2023-01-04
CN114377125A (zh) 2022-04-22
EA037288B1 (ru) 2021-03-04
US20210324070A1 (en) 2021-10-21
JP7142200B2 (ja) 2022-09-27
CN114732899A (zh) 2022-07-12
MA41314A (fr) 2017-11-14
WO2016110806A2 (en) 2016-07-14
IL253247B (en) 2022-04-01
AU2021250850A1 (en) 2021-11-04
EA201791227A1 (ru) 2017-12-29
EP3242684A2 (en) 2017-11-15
IL253247A0 (en) 2017-08-31
WO2016110806A3 (en) 2016-10-20

Similar Documents

Publication Publication Date Title
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201790398A1 (ru) Способы лечения заболевания печени
EA201690549A1 (ru) Арилэфиры и их применения
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
CL2017000050A1 (es) Terapia de combinación para el cáncer
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12018500701A1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине